Management of asthma in preschool children with inhaled corticosteroids and leukotriene receptor antagonists.
OBJECTIVE
The aim of this article is to review the recently published studies addressing various treatment approaches for asthma in preschool children.


RESULTS
The heterogeneity of wheezing in the preschool years complicates the study of asthma in this age group. Once children at highest risk for persistence of wheezing are identified, various management strategies may be thoroughly studied. Several recent studies have confirmed the efficacy and safety of both inhaled corticosteroids and leukotriene receptor antagonists in the management of early childhood asthma. In addition to examining clinical efficacy, studies investigating the effects of these treatment modalities on the underlying airway inflammation have recently increased in number and quality and confirm the anti-inflammatory actions of these therapeutic strategies in the preschool child with asthma.


CONCLUSIONS
Evidence for the preferred treatment strategies for persistent asthma in young children remains incomplete. Based on the current body of evidence, there is rationale for further investigation of these management strategies, including direct comparisons between inhaled corticosteroids and leukotriene receptor antagonists, as well as the role of long-acting beta-agonists, potentially targeting the subpopulations of early childhood with wheezing who are at highest risk for persistence of asthma symptoms.
Bacharier
Leonard B
LB
Department of Pediatrics, Division of Allergy and Pulmonary Medicine, Washington University School of Medicine and St. Louis Children's Hospital, One Children's Place, St. Louis, MO 63110, USA. Bacharier_L@kids.wustl.edu
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage* / Q000009:adverse effects; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D018849:Controlled Clinical Trials as Topic; D006801:Humans; D020024:Leukotriene Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D020024:Leukotriene Antagonists